Roche ’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results
IMscin001 study showed non-inferior levels of cancer immunotherapyTecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancerAdministered under the skin, the subcutaneous formulation reduces time spent receiving treatment to just minutes, compared with up to an hour for IV infusionData will be submitted to health authorities globally, including the US Food and Drug Administration and European Medicines AgencyBasel, 2 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMscin001 study evaluating a subcutaneous form...
Source: Roche Media News - August 2, 2022 Category: Pharmaceuticals Source Type: news
Ghana: World Hepatitis Day, July 28 (1)
[Ghanaian Times] The burden of hepatitis B infection is highest in the WHO Western Pacific Region and the WHO African Region, where 116 million and 81 million people, respectively, are chronically infected. In 2019, hepatitis B resulted in an estimated 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Hepatitis B can be prevented by vaccines that are safe, available and effective. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news
Tumor Size, Not Small Vessel Invasion, Predicts Survival in HCC Tumor Size, Not Small Vessel Invasion, Predicts Survival in HCC
This study reassessed the current tumor staging criteria for hepatocellular carcinoma, proposing a modification that tumor size, not small vessel invasion, more accurately predicts survival.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 28, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Investor Update - July 18, 2022 Category: Pharmaceuticals Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Media News - July 18, 2022 Category: Pharmaceuticals Source Type: news
113-Gene Signature May Predict Long-Term HCC Risk in NAFLD
TUESDAY, July 12, 2022 -- A 113-gene signature may predict long-term risk for incident hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD), according to a study published online June 22 in Science Translational... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2022 Category: Pharmaceuticals Source Type: news
HCV Eradication in HCC and Decreased Hepatic Functional Reserve HCV Eradication in HCC and Decreased Hepatic Functional Reserve
Does DAA therapy after hepatocellular carcinoma treatment benefit patients with advanced-stage HCC or HCC with decompensated cirrhosis?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
High Residual Liver Cancer Risk in HCV-Cured Cirrhosis High Residual Liver Cancer Risk in HCV-Cured Cirrhosis
Patients with cirrhosis cured of hepatitis C have a 410 times greater risk of hepatocellular carcinoma than the general population and need regular screening, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Hep C Cure Aside, Some Patients Still Benefit From Liver Cancer Screening
(MedPage Today) -- Hepatocellular carcinoma (HCC) risk declined but remained high enough for screening in the first 7 years for some patients cured of their hepatitis C virus infections with direct-acting antivirals, an observational study showed... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 30, 2022 Category: Primary Care Source Type: news
Coffee, Tea May Be Protective Against Liver Cancer
(MedPage Today) -- Certain dietary habits such as higher alcohol intake were associated with a higher risk of hepatocellular carcinoma (HCC), while others such as coffee and tea drinking were linked with a lower risk, according to a large Mendelian... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 10, 2022 Category: Gastroenterology Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Radiation Segmentectomy Efficacious for Unresectable Liver Cancer
MONDAY, June 6, 2022 -- For patients with unresectable very early to early-stage hepatocellular carcinoma with suboptimal location for ablation, radiation segmentectomy is efficacious with few high-grade adverse events, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2022 Category: Pharmaceuticals Source Type: news
CT radiomics helps predict HCC recurrence after liver transplant
A CT radiomics nomogram can preoperatively predict if a hepatocellular carcinom...Read more on AuntMinnie.comRelated Reading:
ASTRO releases EBRT guidelines for liver cancer treatment
New tracer bests FDG for diagnosing liver cancer
PET identifies early responders to liver cancer treatment
AI can identify hepatocellular carcinoma on liver CT exams (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 6, 2022 Category: Radiology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Media News - May 11, 2022 Category: Pharmaceuticals Source Type: news
